Product List
Total Page：16
File Type：pdf, Size：1020Kb
Load more
Recommended publications
-
Environmental Protection Agency § 117.3
Environmental Protection Agency § 117.3 (4) Applicability date. This paragraph TABLE 117.3—REPORTABLE QUANTITIES OF (i) is applicable beginning on February HAZARDOUS SUBSTANCES DESIGNATED PUR- 6, 2020. SUANT TO SECTION 311 OF THE CLEAN (j) Process waste water means any WATER ACT—Continued water which, during manufacturing or Cat- RQ in pounds processing, comes into direct contact Material egory (kilograms) with or results from the production or use of any raw material, intermediate Ammonium benzoate ...................... D ...... 5,000 (2,270) Ammonium bicarbonate .................. D ...... 5,000 (2,270) product, finished product, byproduct, Ammonium bichromate ................... A ....... 10 (4.54) or waste product. Ammonium bifluoride ...................... B ....... 100 (45.4) Ammonium bisulfite ......................... D ...... 5,000 (2,270) [44 FR 50776, Aug. 29, 1979, as amended at 58 Ammonium carbamate .................... D ...... 5,000 (2,270) FR 45039, Aug. 25, 1993; 65 FR 30904, May 15, Ammonium carbonate ..................... D ...... 5,000 (2,270) 2000; 80 FR 37112, June 29, 2015; 83 FR 5208, Ammonium chloride ........................ D ...... 5,000 (2,270) Feb. 6, 2018] Ammonium chromate ...................... A ....... 10 (4.54) Ammonium citrate dibasic ............... D ...... 5,000 (2,270) Ammonium fluoborate ..................... D ...... 5,000 (2,270) § 117.2 Abbreviations. Ammonium fluoride ......................... B ....... 100 (45.4) NPDES equals National Pollutant Ammonium hydroxide ..................... C -
Subject: Manufacturing of Synthetic Organic Chemicals (API's: 400Kg
Subject: Manufacturing of Synthetic Organic Chemicals (API’s: 400Kg/day + R&D: 33.3Kg/day) at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh by M/s. Balaji Chirex Pvt. Ltd., - reg. Project proposal: M/s. Balaji Chirex Pvt. Ltd., proposed to establish a Synthetic Organic Chemical Manufacturing Unit at Plot No. 4, Industrial Park, Attivaram Village, Ozili Mandal, SPSR Nellore District, Andhra Pradesh. The company acquired 4.515 acres of land for the proposed plant and allocated 1.49 acres of the area for green belt. The site is surrounded by internal IDA road in north direction, Shimoga Life Sciences Pvt. Ltd., in east direction and open plots in south and west directions. The nearest human settlement from the site is Attivaram village located at distance of 1.1 km from the site. Mamidi Kalva is at a distance of 4.28 km in southwest direction, flowing from northeast to southwest. Attivaram RF at a distance of 0.5 Km in east, Jayampu RF at a distance of 7 Km in northwest, Permidi RF at a distance of 5 Km in southwest and Sangavaram RF at a distance of 4.5 Km in southwest directions respectively. There are no national parks or sanctuaries within 10 km radius of the site. Total capital cost of the project is Rs. 5 Crores. Manufacturing capacity is presented as follows; Manufacturing Capacity S.No Name of the Product Capacity Kg/Month Kg/Day 1 Alfuzosin 50 1.7 2 Allantion 200 6.7 3 Aripiprazole 100 3.3 4 Calcium Ascorbate 500 16.7 5 Calcium Aspartate 1000 33.3 6 Calcium Citrate Malate 2000 -
Oral Magnesium Gly Magnesium Glycerophosphate Ceroph
pat hways Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate Evidence summary Published: 29 January 2013 nice.org.uk/guidance/esuom4 Key points from the evidence The content of this evidence summary was up-to-date in January 2013. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA or NICE websites for up-to-date information. Magnesium glycerophosphate is a magnesium salt that is available as a tablet, capsule, liquid solution or liquid suspension for oral use. The British national formulary (BNF) states that oral magnesium glycerophosphate is a suitable preparation to prevent recurrence of symptomatic hypomagnesaemia in people who have already been treated for this condition. This evidence summary looks at the use of oral magnesium glycerophosphate in patients who have previously been treated with an intravenous infusion of magnesium. Oral magnesium glycerophosphate does not have UK marketing authorisation for this or any other indication, and therefore it is an unlicensed medicine in the UK. No published clinical trials comparing the efficacy of oral magnesium glycerophosphate with placebo or any form of active treatment for preventing recurrent hypomagnesaemia after treatment with intravenous magnesium were identified. The only videncee found was from 3 case reports describing the use of oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia in adults after intravenous treatment. © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- Page 1 of conditions#notice-of-rights). 17 Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4) Two of the 3 case reports concerned patients who had short bowel syndrome due to surgical resection. -
Used at Rocky Flats
. TASK 1 REPORT (Rl) IDENTIFICATION OF CHEMICALS AND RADIONUCLIDES USED AT ROCKY FLATS I PROJECT BACKGROUND ChemRisk is conducting a Rocky Flats Toxicologic Review and Dose Reconstruction study for The Colorado Department of Health. The two year study will be completed by the fall of 1992. The ChemRisk study is composed of twelve tasks that represent the first phase of an independent investigation of off-site health risks associated with the operation of the Rocky Flats nuclear weapons plant northwest of Denver. The first eight tasks address the collection of historic information on operations and releases and a detailed dose reconstruction analysis. Tasks 9 through 12 address the compilation of information and communication of the results of the study. Task 1 will involve the creation of an inventory of chemicals and radionuclides that have been present at Rocky Flats. Using this inventory, chemicals and radionuclides of concern will be selected under Task 2, based on such factors as the relative toxicity of the materials, quantities used, how the materials might have been released into the environment, and the likelihood for transport of the materials off-site. An historical activities profile of the plant will be constructed under Task 3. Tasks 4, 5, and 6 will address the identification of where in the facility activities took place, how much of the materials of concern were released to the environment, and where these materials went after the releases. Task 7 addresses historic land-use in the vicinity of the plant and the location of off-site populations potentially affected by releases from Rocky Flats. -
Marketing Research on Dietary Supplements for Periodontitis in Patient Diabetes
Original Study MARKETING RESEARCH ON DIETARY SUPPLEMENTS FOR PERIODONTITIS IN PATIENT DIABETES Galyna Biloklytska, Svitlana Viala, Alina Koval* National Medical Academy of Postgraduate Education named after P. L. Shupyk, Kyiv, Ukraine. ABSTRACT The vast majority of periodontal diseases are inflammatory and can develop under the influence of both local causes and the combined action of common (endogenous) and local factors against the background of changes in the reactivity of the body. In the pathogenesis of the development of periodontal diseases in patients with diabetes, the main role is given to angiopathies. Since periodontitis is characterized by various vascular disorders, which are largely similar to diabetic angiopathy, it is not easy to prove the presence of the latter with periodontitis. So some authors argue this, while, others deny it. The starting point of diabetic microangiopathies is a violation of carbohydrate metabolism, as well as a violation of glycosamine metabolism, which determines the functional and structural integrity of the vascular basement membrane. Key words: producing countries, periodontitis, diabetes mellitus, dietary supplements, medicines, dentistry. Introduction the treatment and prevention of such pathology, as periodontitis in patients with diabetes. Nowadays, the problem of treatment and rehabilitation of patients with periodontitis is quite actual, as there is an The search for modern drugs and perspective combinations increase in morbidity among people of working age, of microelements for treatment, both internally and locally, increasing demands on appearance as a factor that plays an using applications on periodontal tissues in patients with important role in professional and personal success in various types of diabetes, involves marketing analysis of society. -
Appendix C: Natural Resources and Environmental Protection
A Appendix C: P Natural Resources P and Environmental E Protection Act (NREPA) Part 31 – N Part 5 Rules D • Applicability Flow Chart I • Part 5 Rules with Notes X C APPENDIX C: NREPA Part 31 – Part 5 Rules Applicability Flow Chart - Part 5 Rules Spillage of Oil and Polluting Materials Review the administrative rules (R 324.2001 – R 324.2009) on the following pages and ask the questions below to determine if the Part 5 requirements apply. Does the facility meet the definition of an oil storage or on-land facility per R 324.2001 (f) or (g)? No Yes Does the facility have polluting materials that all meet the small container exemption or are regulated by (and in compliance with) another Yes Not subject to Part 5 requirements. program listed in R 324.2003 excluding R 324.2003 (1)(b)? No Does the facility have polluting materials in regulated Threshold Management Quantities (TMQs) per R 324.2002 (f)? No Polluting materials include mixtures containing 1% or more, by weight, of any substances listed below. SALT LISTED CHEMICALS OIL R 324.2009 Solid form - 5 tons Single container or tank having 660 gallon storage or Liquid form - 1,000 gallons Outdoors – 440 pounds capacity Indoors – 2,200 pounds Total capacity of 1,320 gallons above ground storage REQUIREMENTS o Pollution Incident Prevention Plan (PIPP) – R 324.2006 REQUIREMENTS Including notification requirements to EGLE , local health o Use Area & Indoor Storage – R 324.2005 department, and local emergency planning committee o Surveillance – R 324.2004 o Secondary Containment – R 324.2005 o -
MAGNESIUM and EHLERS-DANLOS SYNDROME PART ONE: *WHY* PERSONS with EDS NEED to KNOW ABOUT MAGNESIUM ©2013 Heidi Collins, MD
MAGNESIUM AND EHLERS-DANLOS SYNDROME PART ONE: *WHY* PERSONS WITH EDS NEED TO KNOW ABOUT MAGNESIUM ©2013 Heidi Collins, MD Everybody should know about magnesium. It’s just that important. “Magnesium is needed for more than 300 biochemical reactions in the body. It helps maintain normal muscle and nerve function, keeps heart rhythm steady, supports a healthy immune system, and keeps bones strong. Magnesium also helps regulate blood sugar levels, promotes normal blood pressure, and is known to be involved in energy metabolism and protein synthesis.” – From Magnesium Fact Sheet from the National Institutes of Health (PLEASE TAKE THE TIME TO READ): http://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ (Notice also the links provided at the bottom of the Fact Sheet to many of the 62 references.) What are some of the symptoms of magnesium deficiency? “Magnesium deficiency can affect virtually every organ system of the body. With regard to skeletal muscle, one may experience twitches, cramps, muscle tension, muscle soreness, including back aches, neck pain, tension headaches and jaw joint (or TMJ) dysfunction. Also, one may experience chest tightness or a peculiar sensation that he can't take a deep breath. Sometimes a person may sigh a lot. … Symptoms involving impaired contraction of smooth muscles include constipation; urinary spasms; menstrual cramps; difficulty swallowing or a lump in the throat-especially provoked by eating sugar; photophobia, especially difficulty adjusting to oncoming bright headlights in the absence of eye disease; and loud noise sensitivity from stapedius muscle tension in the ear. … The central nervous system is markedly affected. Symptoms include insomnia, anxiety, hyperactivity and restlessness with constant movement, panic attacks, agoraphobia, and premenstrual irritability. -
Safety Data Sheet
SAFETY DATA SHEET Preparation Date: 1/12/2016 Revision Date: 2/13/2018 Revision Number: G2 1. IDENTIFICATION Product identifier Product code: F1002 Product Name: FERRIC AMMONIUM OXALATE, GRANULAR Other means of identification Synonyms: Ethanedioic acid, ammonium iron(3+) salt (3:3:1), trihydrate Ethanedioic acid, iron (3+) ammonium salt, hydrate (3:1:3:3) Oxalic acid, ammonium iron (3+) salt (3:3:1), trihydrate Iron ammonium oxalate, (NH4)3Fe(C2O4)3, trihydrate Ammonium iron oxalate, (NH4)3Fe(C2O4)3, trihydrate CAS #: 13268-42-3 RTECS # LJ8932000 (for anhydrous form CAS no. 14221-47-7) CI#: Not available Recommended use of the chemical and restrictions on use Recommended use: In photography. blueprpints. Coloring of aluminum and aluminum alloys. Uses advised against No information available Supplier: Spectrum Chemical Mfg. Corp 14422 South San Pedro St. Gardena, CA 90248 (310) 516-8000 Order Online At: https://www.spectrumchemical.com Emergency telephone number Chemtrec 1-800-424-9300 Contact Person: Martin LaBenz (West Coast) Contact Person: Ibad Tirmiz (East Coast) 2. HAZARDS IDENTIFICATION Classification This chemical is considered hazardous according to the 2012 OSHA Hazard Communication Standard (29 CFR 1910.1200) Considered a dangerous substance or mixture according to the Globally Harmonized System (GHS) Acute toxicity - Oral Category 4 Acute toxicity - Dermal Category 4 Skin corrosion/irritation Category 2 Serious eye damage/eye irritation Category 2 Specific target organ toxicity (single exposure) Category 3 Label elements Warning -
Georgia State Forensic Drugs
Comprehensive Forensic FT-IR Collection Library Listing – 4,286 spectra This extensive library contains materials not only of forensic interest but also for general problem solving and identification of unknown substances in industry and academia. The wide range of items include drugs, clandestine lab chemicals, explosives, paints, fabrics, dyes, polymers, inorganic compounds, pigments, adhesives, and other common materials. The library consists of 4,286 spectra that were acquired from a wide range of laboratories involved in forensic investigations. The collection includes the following classes of compounds: • Drugs of abuse, scheduled materials • Pharmaceuticals, vitamins and excipients • Clandestine lab materials and intermediates • Solvents, organic chemicals and hazardous chemicals • Accelerants • Lubricants and natural oils • Explosives, pyrotechnics, primers, powders and boosters • Herbal and plant material and fibers • Automobile paint vehicles, pigments, primers and clear coats • Textiles, natural and man-made fibers, carpet materials • Paints, coatings, varnishes, oils • Dyes and stains • Polymers, monomers, copolymers, plasticizers and rubbers • Inorganics, pigments, minerals and clays • Tape, adhesives, sealants, glues, caulks and putties • Crystal test derivatives and intermediates • Household chemicals, cleaning agents, surfactants and pesticide All spectra were measured using micro or macro Diamond ATR, thin films on salt windows or KBr pellets at 4 cm-1 spectral resolution. Comprehensive Forensic FT-IR Collection Index -
Otto-Catalog-2019-20.Pdf
Lab Chemicals & More..... Otto Catalog 2019-20 1 CODE PRODUCT NAME CAS NO. PACKING RATE ` PACKING RATE ` A 1214 ABSCISIC ACID practical grade 10% 14375-45-2 100mg 2007 1gm 13059 A 1215 ABSCISIC ACID for biochemistry 99% 14375-45-2 25mg 1395 100mg 3609 500 mg 17469 A 1217 (7-AMINO CEPHALOSPORANIC ACID) 7-ACA 98% 957-68-6 1gm 2403 5gm 9396 A 1225 ACACIA 9000-01-5 500gm 504 5kg 4392 A 1226 ACACIA spray dried powder 9000-01-5 500gm 684 5kg 6309 A 1227 ACACIA GR 9000-01-5 500gm 828 5kg 7407 A 0855 ACARBOSE, >95% 56180-94-0 1 gm 18099 A 1229 ACENAPHTHENE pract 83-32-9 100gm 306 500gm 1395 5 kg 11907 A 1230 ACENAPHTHENE for synthesis 97% 83-32-9 100gm 450 500gm 1692 A 1231 ACENAPHTHENE GR for HLPC 83-32-9 100gm 1359 500gm 5533 A 1234 ACES BUFFER 99% 7365-82-4 5gm 864 25gm 2385 [N-(2-Acetamido)-2-aminoethane sulfonic acid] 100 gm 8739 A 1233 ACETALDEHYDE 20-30% solution for synthesis 75-07-0 500ml 477 5lt 4095 A 1235 ACETAMIDE for synthesis 99% 60-35-5 500 gm 801 A 1240 ACETAMIDINE CHLORIDE for synthesis 124-42-5 100gm 3159 250gm 7830 A 1242 N-(2-ACETAMIDO) IMINODIACETIC ACID (ADA BUFFER) 26239-55-4 25gm 855 100gm 2592 250 gm 5994 A 1245 ACETANILIDE for synthesis 98.5% 103-84-4 500gm 918 5kg 8289 A 1248 ACETATE BUFFER SOLUTION pH 4.6 - - - - - 500ml 180 5lt 1449 A 1250 ACETIC ACID glacial 99% 64-19-7 500ml 207 5lt 1602 A 1251 ACETIC ACID glacial GR 99%+ 64-19-7 500ml 252 5lt 1908 A 1252 ACETIC ACID GLACIAL GR 99.7% 64-19-7 500ml 315 5lt 1998 A 1253 ACETIC ACID GLACIAL EL 99.9% 64-19-7 500ml 378 5lt 2502 A 1254 ACETIC ACID 99.8% for HPLC 64-19-7 -
Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine 2013
Nucleosides, Nucleotides, Heterocyclic Compounds, Pyridine, Pyrimidine, Azaindole, Quinoline, Thiazole, Isatin, Phenanthrene, Thiophene We declare that some of the listed products might be protected by valid patents. They are only for scientific research and development purpose. They are not offered for sales in countries where the sales of such products constitutes patents infringement. The liability for patents checking and patents infringement is exclusive at buyers risk! I2CNS LLC CANNOT BE HELD LIABLE FOR ANY VIOLATIONS OF PATENT RIGHTS CAUSED BY CUSTOMERS. CAS No. Product Name and Description 26988-72-7 1-METHYL-DL-TRYPTOPHAN 68886-07-7 2-Fluoro-4-hydroxyphenylaceticacid 72607-53-5 N-(3-AMINOPROPYL)METHACRYLAMIDE 171049-41-5 7-AMINO-3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLICACIDTERT- BUTYLESTER 885280-38-6 (3-OXO-CYCLOHEXYL)-CARBAMICACIDTERT-BUTYLESTER 186826-86-8 MOXIFLOXACIN HCL 102735-53-5 L-CYCLOPROPYLALANINE 145100-50-1 2-[N,N-BIS(TRIFLUOROMETHYLSULFONYL)AMINO]PYRIDINE 143491-57-0 Emtricitabine 39809-25-1 2-Amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one 147127-20-6 Tenofovir 716-39-2 2,3-NAPHTHALENEDICARBOXYLICANHYDRIDE 4333-62-4 1,3-DIMETHYLIMIDAZOLIUMIODIDE 108-45-2 m-Phenylenediamine 1961-72-4 R-(3)-HYDROXYMYRISTICACID 131-48-6 N-Acetylneuraminicacid 88196-70-7 (R)-1-(3-Methoxyphenyl)ethylamine 680-31-9 Hexamethylphosphoramide 486-66-8 Daidzein 872-50-4 1-Methyl-2-pyrrolidinone 425378-68-3 2-FLUORO-5-NITROPHENYLBORONICACIDPINACOLESTER 115651-29-1 5-ACETYL-2-AMINO-4-HYDROXYBENZOICACID 115269-99-3 N,N-BIS-BOC-N-ALLYLAMINE -
CHELATED MINERALS Addressing Key Challenges in Mineral Supplementation
NATURAL MEDICINE JOURNAL RESEARCH GUIDE SPONSORED BY ALBION MINERALS CHELATED MINERALS Addressing Key Challenges in Mineral Supplementation Author: Sarah Cook, ND © 2018 IMPACT Health Media, Inc. All rights reserved. This publication may not be reproduced or distributed in any form without written permission from IMPACT Health Media, Inc. Minerals affect nearly all physiologic functions in the human body. Minerals are necessary cofactors for hun- Industrial agricultural practices, food dreds of biochemical reactions as well as essential for nerve conduction, muscle contraction, bone strength, processing, chronic stress, over-exercise, immune function, energy production, and oxygen trans- and poor dietary choices increase the risk of port to name a few. Mineral status influences metabolic mineral deficiencies health, cardiovascular health, prostate health, reproduc- tive health, cognition, and more. Although the human body tightly regulates the avail- ability of minerals and has mechanisms to store them for later use, minerals cannot be endogenously produced. To fulfill the ongoing requirements of the body, people must regularly consume the essential minerals (table 1) from exogenous sources. Table 1. Essential Minerals* Macro- Trace Ultratrace minerals Minerals Minerals Calcium Copper Chromium of people worldwide have inadequate zinc intake. Insuf- Chloride Iron Molybdenum ficiencies in these minerals can contribute to anemia, Magnesium Zinc Vanadium mood disorders, infertility, and more. Potassium Fluoride Iodine Sodium Manganese Selenium Supplementation is sometimes the best or only way Phosphorus Boron to correct mineral deficiencies and to achieve optimal physiologic levels. Choosing the best supplement, * Macrominerals are present in large amounts in the however, can be complicated. This research guide raises body, trace minerals are present in small amounts, and 3 key challenges posed by mineral supplementation and ultratrace minerals are consumed in less than 1 mg/day.